Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1794830 | 0.97 | — | — | |
| SCHEMBL1797776 | 0.86 | — | — | |
| SCHEMBL78649 | 0.74 | EPHX1 (0.41) | SIGMAR1EPHX1HIF1AALDH1A1KDM4E | |
| SCHEMBL6649524 | 0.74 | SIGMAR1 (0.40) | NOS2SIGMAR1EPHX1HIF1AALDH1A1 | |
| SCHEMBL7388666 | 0.73 | NOS2 (0.52) | NOS2KDM4ENOS3NOS1 | |
| SCHEMBL3983669 | 0.70 | — | — | |
| SCHEMBL3732008 | 0.68 | ALDH1A1 (0.39) | SIGMAR1EPHX1HIF1AALDH1A1KDM4E | |
| SCHEMBL23736060 | 0.67 | SIGMAR1 (0.54) | NOS2SIGMAR1EPHX1HIF1AALDH1A1 | |
| SCHEMBL1797463 | 0.67 | SIGMAR1 (0.54) | NOS2SIGMAR1EPHX1HIF1AALDH1A1 | |
| SCHEMBL25333580 | 0.67 | SIGMAR1 (0.54) | NOS2SIGMAR1EPHX1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8618122-B2 | Compound having acidic group which may be protected, and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | NOS2 2577/4885SIGMAR1 1677/4885EPHX1 1851/4885 |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | NOS2 3627/4885SIGMAR1 639/4885EPHX1 889/4885 |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | NOS2 3107/4885SIGMAR1 1321/4885EPHX1 900/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | NOS2 335/4885SIGMAR1 756/4885EPHX1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.